Interestingly, the risk of progression from CHIP to MDS to AML is significantly heterogeneous among the patients despite the fact that the precursor states of MDS and AML are associated with similar gene mutations conferring a clonal advantage [15, 16]. The gene discussed is STUB1; the disease is acute myeloid leukemia.